Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EpiATLAS - a reference for human epigenomic research.

bioRxiv : the preprint server for biology·2026
Same author

Correcting spatial transcriptomics data affected by a prevalent transcript leakage problem across platforms, species, and tissues.

bioRxiv : the preprint server for biology·2026
Same author

HIRA-mediated H3.3 deposition preserves hepatocyte cell identity during liver aging.

Research square·2026
Same author

SAKURA: a knowledge-guided approach to recovering important, rare signals from single-cell data.

Genome biology·2026
Same author

Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential.

Communications biology·2025
Same author

A knowledge-guided approach to recovering important rare signals from high-dimensional single-cell data.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jun 20, 2026

Mining Spatial Transcriptomics Datasets using DeepSpaceDB
10:16

Mining Spatial Transcriptomics Datasets using DeepSpaceDB

Published on: September 5, 2025

Spatial transcriptomics in Alzheimer's disease: technologies, challenges and discoveries.

Christina Huan Shi1, Juan C Piña-Crespo2, Kevin Y Yip2,1,3

  • 1Center for Data Science and Artificial Intelligence, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037 USA.

Molecular Neurodegeneration Advances
|June 19, 2026
PubMed
Summary
This summary is machine-generated.

Spatial transcriptomics reveals cellular changes in Alzheimer's disease (AD) brains. This technology, analyzing gene activity in specific locations, offers new insights into AD pathology and potential therapeutic targets.

Keywords:
Alzheimer’s diseaseAβ plaquesCellular response to AD pathologyCell–cell interactionPathological AD microenvironmentRegional vulnerability and resilienceSpatial transcriptomicsTau

More Related Videos

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
04:22

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Related Experiment Videos

Last Updated: Jun 20, 2026

Mining Spatial Transcriptomics Datasets using DeepSpaceDB
10:16

Mining Spatial Transcriptomics Datasets using DeepSpaceDB

Published on: September 5, 2025

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
04:22

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Area of Science:

  • Neuroscience
  • Genomics
  • Biotechnology

Background:

  • Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive decline.
  • Key pathologies include beta-amyloid (Aβ) plaques and neurofibrillary tau tangles.
  • Understanding cellular interactions with these pathologies is crucial.

Purpose of the Study:

  • To review spatial transcriptomic technologies and analytical pipelines for AD research.
  • To summarize current findings from spatial transcriptomics in the AD brain.
  • To discuss limitations and future directions of these technologies in neurodegenerative disease research.

Main Methods:

  • Review of current spatial transcriptomic technologies.
  • Analysis of spatial and single-cell transcriptomic data from AD mouse models and human brains.
  • Examination of analytical pipelines used in AD research.

Main Results:

  • Spatial transcriptomics enables characterization of cellular changes in the AD brain.
  • These methods provide insights into how AD pathologies affect different cell types.
  • A convergence of AD research, imaging, and transcriptomics heralds a new era.

Conclusions:

  • Spatial transcriptomics is a powerful tool for understanding cellular heterogeneity in AD.
  • Despite current limitations, the evolution of spatial transcriptomics promises significant advances.
  • Combined with other data modalities, it offers a promising future for AD and related disorders.